Chugai Pharmaceutical Co., Ltd.
4519
Helyezés a részvények között
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Részvényárfolyam
$41.60
Piaci kapitalizáció
$68.46B
Változás (1 nap)
0.94%
Változás (1 év)
-12.56%
Ország
JP
Kereskedés Chugai Pharmaceutical Co., Ltd. (4519)
Kategória
Healthcare
Chugai Pharmaceutical Co., Ltd. (4519) nyeresége
Nyereség ekkor: 2026 TTM: 0
Chugai Pharmaceutical Co., Ltd. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége 0. 2026 évben a vállalat 0 nyereséget ért el, megegyezik a 2026 év nyereségéhez, amely 0 volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Chugai Pharmaceutical Co., Ltd. nyereségtörténete 2003 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2025 | $3.81B | 10.18% |
| 2024 | $3.46B | 9.91% |
| 2023 | $3.15B | -22.32% |
| 2022 | $4.05B | 11.19% |
| 2021 | $3.64B | 26.14% |
| 2020 | $2.89B | 51.00% |
| 2019 | $1.91B | 72.67% |
| 2018 | $1.11B | 28.63% |
| 2017 | $861.20M | 35.29% |
| 2016 | $636.58M | -12.20% |
| 2015 | $725.04M | 14.00% |
| 2014 | $635.98M | -12.96% |
| 2013 | $730.71M | -13.05% |
| 2012 | $840.36M | 13.52% |
| 2011 | $740.25M | -8.49% |
| 2010 | $808.92M | -16.02% |
| 2009 | $963.18M | 38.51% |
| 2008 | $695.38M | 17.04% |
| 2007 | $594.11M | 12.26% |
| 2006 | $529.22M | -27.64% |
| 2005 | $731.36M | 30.51% |
| 2004 | $560.37M | 21.93% |
| 2003 | $459.59M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
